ETH
CLDI.WS

Exos TFP Holdings’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Exos TFP Holdings’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$5.25K Hold
105,000
– – ﹤0.01% 136
2023
Q3 		$23.1K Buy
+105,000
New +$19.2K 0.01% 137

Other funds holding CLDI.WS

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Exos TFP Holdings's CLDI.WS Position: Q4 2023 in Review

Exos TFP Holdings held its Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) position steady in Q4 2023 at 105,000 shares worth $5.25K. The position accounts for ﹤0.01% of the portfolio, ranked #136.

Exos TFP Holdings first reported a position in CLDI.WS in Q3 2023 and has held it in 2 quarters since. The position peaked at $23.1K in Q3 2023. 17 funds tracked by Wall St. Rank hold CLDI.WS as of Q4 2023.

  • Exos TFP Holdings held 105,000 shares of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 worth $5.25K as of Q4 2023.
  • Exos TFP Holdings left its Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 share count unchanged in Q4 2023.
  • Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 made up ﹤0.01% of Exos TFP Holdings's portfolio in Q4 2023, its #136 holding.
  • Exos TFP Holdings first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q3 2023 and has held it in 2 quarters since.
  • Exos TFP Holdings's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $23.1K in Q3 2023.
  • 17 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2023.

Based on Exos TFP Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.